We are live on
!
Find out more
TAM
TFG Asset Management Portfolio holdings
AUM
$635M
Turnover
36.96%
1-Year Est. Return
28.07%
This Fund
S&P 500
This Quarter
Est. Return
+13.2%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$635M
AUM Growth
+$120M
(+23%)
Cap. Flow
+$71.2M
Cap. Flow
% of AUM
11.21%
Top 10 Holdings %
Top 10 Hldgs %
74.01%
Holding
46
New
10
Increased
16
Reduced
5
Closed
7
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
1.2
years
Top 20 Avg Time Held Equity + Options
1.2
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UiPath
PATH
|
+$61.3M |
| 2 |
Alkami Technology
ALKT
|
+$9.91M |
| 3 |
Celcuity
CELC
|
+$7.4M |
| 4 |
Relay Therapeutics
RLAY
|
+$5.64M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$4.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Warner Bros
WBD
|
+$18.2M |
| 2 |
Praxis Precision Medicines
PRAX
|
+$5.14M |
| 3 |
Axsome Therapeutics
AXSM
|
+$4.35M |
| 4 |
Soleno Therapeutics
SLNO
|
+$3.42M |
| 5 |
MapLight Therapeutics
MPLT
|
+$2.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 61.09% |
| 2 | Healthcare | 29.27% |
| 3 | Energy | 5.33% |
| 4 | Miscellaneous | 3.27% |
| 5 | Communication Services | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Nektar Therapeutics
NKTR
$1.31B
| $6.07M | 0.96% |
86,996
-16,041
| -16% | -$1.17M |
2025 Q4
2 quarters
|
|
27
Amylyx Pharmaceuticals
AMLX
$3.54B
| $5.35M | 0.84% |
297,926
-19,951
| -6% | -$309K |
2025 Q2
4 quarters
|
|
28
Acadia Pharmaceuticals
ACAD
$3.41B
| $4.25M | 0.67% |
167,875
+23,255
| +16% | +$512K |
2026 Q1
1 quarter
|
|
29
CALL
Ultragenyx Pharmaceutical
RARE
$1.49B
| $3.34M | 0.53% |
+100,000
| New | +$2.48M |
2026 Q2
0 quarters
|
|
30
CALL
Silence Therapeutics
SLN
$561M
| $3.29M | 0.52% |
+300,000
| New | +$2.11M |
2026 Q2
0 quarters
|
|
31
Cue Biopharma
CUE
$132M
| $2.96M | 0.47% |
+93,819
| New | +$2.12M |
2026 Q2
0 quarters
|
|
32
Snowflake
SNOW
$114B
| $2.54M | 0.4% |
10,000
| – | – |
2021 Q4
18 quarters
|
|
33
CALL
Karyopharm Therapeutics
KPTI
$7.77M
| $2.45M | 0.39% |
250,300
+200,300
| +401% | +$1.74M |
2026 Q1
1 quarter
|
|
34
Aclaris Therapeutics
ACRS
$509M
| $2.12M | 0.33% |
+400,000
| New | +$1.78M |
2026 Q2
0 quarters
|
|
35
CALL
Agios Pharmaceuticals
AGIO
$1.91B
| $1.86M | 0.29% |
+50,000
| New | +$1.52M |
2026 Q2
0 quarters
|
|
36
Tectonic Therapeutic
TECX
$419M
| $1.6M | 0.25% |
46,516
+8,928
| +24% | +$262K |
2026 Q1
1 quarter
|
|
37
Monte Rosa Therapeutics
GLUE
$869M
| $1.36M | 0.21% |
+56,052
| New | +$1.06M |
2026 Q2
0 quarters
|
|
38
CALL
Tenax Therapeutics
TENX
$57.6M
| $1.09M | 0.17% |
+75,100
| New | +$959K |
2026 Q2
0 quarters
|
|
|
39
CALL
Amylyx Pharmaceuticals
AMLX
$3.54B
| $153K | 0.02% |
+8,500
| New | +$131K |
2026 Q2
0 quarters
|
|
|
40
Axsome Therapeutics
AXSM
$8.79B
| – | – |
-20,059
| Closed | -$4.35M | – |
|
|
41
Karyopharm Therapeutics
KPTI
$7.77M
| – | – |
-52,984
| Closed | -$460K | – |
|
|
42
Praxis Precision Medicines
PRAX
$6.98B
| – | – |
-15,952
| Closed | -$5.14M | – |
|
|
43
Ultragenyx Pharmaceutical
RARE
$1.49B
| – | – |
-39,473
| Closed | -$980K | – |
|
|
44
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-102,125
| Closed | -$3.42M | – |
|
45
Aardvark Therapeutics
AARD
$84M
| – | – |
-316,621
| Closed | -$1.19M | – |
|
|
46
MapLight Therapeutics
MPLT
$448M
| – | – |
-112,115
| Closed | -$2.28M | – |
|
Similar funds
GRR
GAM
MPIA
AFG
MCM
MAM
BAM
LRIA
TFG Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, TFG Asset Management held 46 positions worth $635M, up 23% from $515M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
TFG Asset Management deployed $71.2M of net new capital in Q2 2026, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Alkami Technology: 600,284 shares worth $10.9M.
By sector, the portfolio is most concentrated in Technology at 61% of assets, down from 63% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Warner Bros, an estimated $18.2M trimmed.
- TFG Asset Management's largest Q2 2026 buy was Alkami Technology: 600,284 shares worth $10.9M.
- TFG Asset Management added most to UiPath in Q2 2026, an estimated $61.3M increase.
- TFG Asset Management's biggest Q2 2026 reduction was Warner Bros, cutting an estimated $18.2M.
- TFG Asset Management fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $5.14M.
- TFG Asset Management's ten largest holdings make up 74% of its $635M portfolio in Q2 2026.
- TFG Asset Management opened 10 new positions and closed 7 in Q2 2026.
- TFG Asset Management's portfolio value rose 23% quarter-over-quarter to $635M.
Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.